Host-defense peptides with therapeutic potential from skin secretions of frogs from the family pipidae.

J Michael Conlon, Milena Mechkarska
Author Information
  1. J Michael Conlon: Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE. jmconlon@uaeu.ac.ae.
  2. Milena Mechkarska: Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE. mpanteva@uaeu.ac.ae.

Abstract

Skin secretions from frogs belonging to the genera Xenopus, Silurana, Hymenochirus, and Pseudhymenochirus in the family Pipidae are a rich source of host-defense peptides with varying degrees of antimicrobial activities and cytotoxicities to mammalian cells. Magainin, peptide glycine-leucine-amide (PGLa), caerulein-precursor fragment (CPF), and xenopsin-precursor fragment (XPF) peptides have been isolated from norepinephrine-stimulated skin secretions from several species of Xenopus and Silurana. Hymenochirins and pseudhymenochirins have been isolated from Hymenochirus boettgeri and Pseudhymenochirus merlini. A major obstacle to the development of these peptides as anti-infective agents is their hemolytic activities against human erythrocytes. Analogs of the magainins, CPF peptides and hymenochirin-1B with increased antimicrobial potencies and low cytotoxicities have been developed that are active (MIC < 5 μM) against multidrug-resistant clinical isolates of Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Stenotrophomonas maltophilia and Klebsiella pneumoniae. Despite this, the therapeutic potential of frog skin peptides as anti-infective agents has not been realized so that alternative clinical applications as anti-cancer, anti-viral, anti-diabetic, or immunomodulatory drugs are being explored.

References

  1. Mol Phylogenet Evol. 2004 Oct;33(1):197-213 [PMID: 15324848]
  2. Clin Infect Dis. 2008 Dec 15;47(12):1537-45 [PMID: 18990064]
  3. Biochimie. 2013 Feb;95(2):429-35 [PMID: 23142129]
  4. Peptides. 2013 Jul;45:1-8 [PMID: 23624316]
  5. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):887-92 [PMID: 17213318]
  6. Biochemistry. 2010 May 18;49(19):4076-84 [PMID: 20387900]
  7. Front Biosci. 2008 May 01;13:4687-706 [PMID: 18508539]
  8. Int J Antimicrob Agents. 2003 Jan;21(1):75-8 [PMID: 12507842]
  9. Peptides. 2013 Dec;50:153-9 [PMID: 24172540]
  10. Diagn Microbiol Infect Dis. 1999 Sep;35(1):45-53 [PMID: 10529881]
  11. BMC Evol Biol. 2011 Apr 27;11:114 [PMID: 21524293]
  12. Acta Biochim Pol. 2011;58(1):111-7 [PMID: 21403917]
  13. Biochem Mol Biol Int. 1998 May;44(6):1119-26 [PMID: 9623765]
  14. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3792-6 [PMID: 1708887]
  15. Biophys J. 2008 Dec 15;95(12):5757-65 [PMID: 18835901]
  16. J Biol Chem. 1986 Apr 25;261(12):5341-9 [PMID: 3957928]
  17. Comp Biochem Physiol Part D Genomics Proteomics. 2011 Jun;6(2):206-12 [PMID: 21498136]
  18. Cancer Res. 1992 Jul 1;52(13):3534-8 [PMID: 1319823]
  19. Syst Biol. 2012 Dec 1;61(6):913-26 [PMID: 22438331]
  20. Syst Biol. 2005 Feb;54(1):111-26 [PMID: 15805014]
  21. Comp Biochem Physiol Part D Genomics Proteomics. 2013 Dec;8(4):352-7 [PMID: 24212286]
  22. Virology. 2004 Jun 1;323(2):268-75 [PMID: 15193922]
  23. J Phys Chem B. 2010 Sep 23;114(37):12018-26 [PMID: 20799752]
  24. Eur Urol. 2006 Jul;50(1):141-7 [PMID: 16476519]
  25. Biochim Biophys Acta. 2009 Aug;1788(8):1656-66 [PMID: 19481533]
  26. Comp Biochem Physiol C Toxicol Pharmacol. 2010 Nov;152(4):467-72 [PMID: 20656059]
  27. Cell Tissue Res. 2011 Jan;343(1):201-12 [PMID: 20640445]
  28. Peptides. 2012 Sep;37(1):113-9 [PMID: 22800690]
  29. Int J Antimicrob Agents. 2012 Apr;39(4):317-20 [PMID: 22326566]
  30. Antimicrob Agents Chemother. 1999 Apr;43(4):782-8 [PMID: 10103181]
  31. Chem Biol Drug Des. 2008 Jul;72(1):58-64 [PMID: 18554256]
  32. Curr Opin Infect Dis. 2012 Aug;25(4):371-7 [PMID: 22766646]
  33. Expert Opin Emerg Drugs. 2012 Sep;17(3):379-91 [PMID: 22780561]
  34. Regul Pept. 2013 Nov 10;187:51-6 [PMID: 24185042]
  35. Biophys J. 2013 Mar 19;104(6):L9-11 [PMID: 23528099]
  36. Antimicrob Agents Chemother. 1999 Mar;43(3):702-4 [PMID: 10049295]
  37. Can J Microbiol. 1990 Aug;36(8):582-4 [PMID: 2245380]
  38. Peptides. 2012 Jun;35(2):269-75 [PMID: 22497805]
  39. Dev Comp Immunol. 2012 May;37(1):19-27 [PMID: 22227319]
  40. Protein Cell. 2010 Feb;1(2):143-52 [PMID: 21203984]
  41. Biochimie. 2014 Jun;101:83-92 [PMID: 24412102]
  42. Methods. 2007 Aug;42(4):349-57 [PMID: 17560323]
  43. Int J Antimicrob Agents. 2004 Apr;23(4):382-9 [PMID: 15081088]
  44. Peptides. 2010 Nov;31(11):1966-72 [PMID: 20705109]
  45. Antimicrob Agents Chemother. 1998 May;42(5):1213-6 [PMID: 9593152]
  46. Comp Biochem Physiol Part D Genomics Proteomics. 2013 Sep;8(3):250-4 [PMID: 23896465]
  47. Expert Opin Investig Drugs. 2006 Aug;15(8):933-46 [PMID: 16859395]
  48. Biol Pharm Bull. 1997 Jul;20(7):805-8 [PMID: 9255424]
  49. Biochemistry. 2012 Dec 21;51(51):10229-35 [PMID: 23194027]
  50. Comp Biochem Physiol Part D Genomics Proteomics. 2012 Sep;7(3):285-91 [PMID: 22687652]
  51. J Zool (1987). 2011 Apr 1;283(4):276-290 [PMID: 21546992]
  52. Peptides. 2011 Jul;32(7):1502-8 [PMID: 21664395]
  53. Peptides. 2012 Jan;33(1):35-43 [PMID: 22123629]
  54. Biochim Biophys Acta. 2010 Apr;1804(4):1020-8 [PMID: 20116461]
  55. Cell Mol Life Sci. 2011 Jul;68(13):2161-76 [PMID: 21573784]
  56. FEBS Lett. 1988 Jun 20;233(2):282-8 [PMID: 3384094]
  57. Comp Biochem Physiol C Toxicol Pharmacol. 2011 Apr;153(3):350-4 [PMID: 21199684]
  58. Cancer Res. 1993 Jul 1;53(13):3052-7 [PMID: 8319212]
  59. FEBS Lett. 1988 Feb 15;228(2):337-40 [PMID: 3125066]
  60. Biochim Biophys Acta. 2001 Nov 26;1550(1):81-9 [PMID: 11738090]
  61. Peptides. 2010 Jun;31(6):989-94 [PMID: 20226221]
  62. Eur J Biochem. 1995 Mar 1;228(2):257-64 [PMID: 7705337]
  63. Cell Mol Life Sci. 2011 Jul;68(13):2303-15 [PMID: 21560068]
  64. J Biol Chem. 1991 Oct 15;266(29):19851-7 [PMID: 1717472]
  65. Antimicrob Agents Chemother. 1992 Jun;36(6):1263-71 [PMID: 1416825]
  66. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5449-53 [PMID: 3299384]
  67. Cytogenet Cell Genet. 1982;34(1-2):149-57 [PMID: 7151486]
  68. Biochem Biophys Res Commun. 2013 Feb 1;431(1):14-8 [PMID: 23291176]
  69. Biopolymers. 2008;90(3):369-83 [PMID: 18098173]
  70. PLoS Genet. 2013;9(8):e1003662 [PMID: 23935531]
  71. Pept Res. 1988 Nov-Dec;1(2):81-6 [PMID: 2980783]
  72. FEBS Lett. 1999 Apr 23;449(2-3):105-10 [PMID: 10338113]
  73. Proc Natl Acad Sci U S A. 1988 Feb;85(3):910-3 [PMID: 3277183]
  74. Biochemistry. 2009 Sep 1;48(34):8083-93 [PMID: 19655791]
  75. Biochim Biophys Acta. 2009 Aug;1788(8):1687-92 [PMID: 18952049]
  76. Dev Comp Immunol. 2009 Dec;33(12):1247-57 [PMID: 19622371]

Word Cloud

Created with Highcharts 10.0.0peptidessecretionsskinfrogsXenopusSiluranaHymenochirusPseudhymenochirusfamilyantimicrobialactivitiescytotoxicitiesfragmentCPFisolatedanti-infectiveagentsclinicaltherapeuticpotentialSkinbelonginggeneraPipidaerichsourcehost-defensevaryingdegreesmammaliancellsMagaininpeptideglycine-leucine-amidePGLacaerulein-precursorxenopsin-precursorXPFnorepinephrine-stimulatedseveralspeciesHymenochirinspseudhymenochirinsboettgerimerlinimajorobstacledevelopmenthemolytichumanerythrocytesAnalogsmagaininshymenochirin-1BincreasedpotencieslowdevelopedactiveMIC<5μMmultidrug-resistantisolatesStaphylococcusaureusEscherichiacoliAcinetobacterbaumanniiStenotrophomonasmaltophiliaKlebsiellapneumoniaeDespitefrogrealizedalternativeapplicationsanti-canceranti-viralanti-diabeticimmunomodulatorydrugsexploredHost-defensepipidae

Similar Articles

Cited By (33)